Pfizer, BridgeBio
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio has said it will provide Attruby for free for the lifetime of any patient who participated in clinical trials of the drug.
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell?
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...
4don MSN
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
Bourla said in a statement that Boshoff was “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the ...
No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback